Indications |
Oral Pruritic skin disorders, Hypersensitivity reactions Adult: 8-16 mg bid. Child: 3-6 yr: 0.3 mg/kg/day, max 8 mg/day. 6-12 yr: 4 mg bid. |
Contraindications |
Neonates; narrow-angle glaucoma; GI tract/urinary outflow obstruction, paralytic ileus. |
Warnings / Precautions |
Elderly; caution in driving; peptic ulcer; epilepsy; severe CV disease, benign prostatic hyperplasia; pregnancy and lactation; asthma, bronchitis; hepatic or renal impairment; Parkinson's disease. |
Adverse Reactions |
Drowsiness, CNS depression, paradoxical excitation (children). Dry mouth, blurring of vision; constipation, retention of urine; bradycardia followed by tachycardia and arrhythmias. GI disturbances; blood dyscrasias; giddiness; hypotension; headache; asthma; tremors; photosensitivity; jaundice; menstrual disorders. |
Drug Interactions |
Potentiates CNS depressant action of alcohol, barbiturates, hypnotics, opioid analgesics, sedatives and neuroleptics. Antimuscarinic effects potentiated by MAOIs, atropine and TCAs. May reduce effect of levodopa. See Below for More methdilazine Drug Interactions |
Food Interactions |
None reported. |
Mechanism of Actions |
Methdilazine, a phenothiazine derivative, is a sedating antihistamine with antimuscarinic and possibly some serotonin-antagonist properties. |
Administration |
May be taken with or without food. |
ATC Classification |
R06AD04 - methdilazine ; Belongs to the class of phenothiazine derivatives used as systemic antihistamines. |
Available As |
|
Methdilazine
Post Review about Methdilazine Click here to cancel reply.
Methdilazine Containing Brands
Methdilazine is used in following diseases
Drug - Drug Interactions of Methdilazine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.